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ABSTRACT
Chronic graft-versus-host disease (cGVHD) is a common late complication of allogeneic stem cell transplanta-
tion (allo-SCT). Some cGVHD patients develop skin lesions, and the skin lesions in sclerodermatous cGVHD
(s-cGVHD) patients resemble those in progressive systemic sclerosis (PSS), which is characterized by impaired
production of circulating endothelial progenitor cells (EPCs). We investigated, retrospectively, whether low
EPC production may promote the development of sclerodermatous lesions in cGVHD. Peripheral blood (PB)
was obtained from 14 healthy volunteers and 27 allo-SCT patients. Five patients developed s-cGVHD.
CD341 cells were purified by using the magnetic cell-sorting separation system, and the CD341/CD1331/vas-
cular endothelial growth factor (VEGF) receptor-21 EPCs were quantified. The endothelial cell colony-forma-
tion potential was evaluated. Serum VEGF and basic fibroblast growth factor (b-FGF) concentrations were
measured by ELISA. The s-cGVHD patients had significantly lower median circulating EPCs frequencies
than non-s-cGVHD patients or control (145 of 20 mL [interquartial range—IQR 107-193] versus 1083.5
[IQR 669.3-2151]; P 5 .0023, and versus 1530.5 [IQR 961.3-2158]; P 5 .0012, respectively). They also had im-
paired median endothelial-forming ability compared to non-s-cGVHD patients or controls (3.8 [IQR 1.0-4.3]
versus 12.8 [IQR 8.8-28.8], and versus 26.4 [IQR 23.6-30.6], respectively; P 5 .0012). Their VEGF and
b-FGF serum levels were also higher than in controls. In conclusion, s-cGVHD patients show findings consis-
tent with those seen in PSS with impaired vasculogenesis that may limit blood perfusion and may contribute to
the development of sclerodermatous lesions.
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Allogeneic stem cell transplantation (allo-SCT) is
an important therapy for hematologic diseasese. How-
ever, despite advances in the procedures and posttrans-
plantation immunosuppressive therapy, over 50% of
allo-SCT recipients develop acute or chronic graft-
versus-host disease (aGHVD, cGVHD). Chronic6GVHD is 1 of the most common late complications,
as it occurs in 25%-80% of transplant recipients [1].
It affects the quality of life of long-term survivors after
allo-SCT, and its clinical signs resemble those of auto-
immune diseases. It has been suggested that fibrotic
manifestations associated with cGVHDmay be caused
by microvessel loss because of cytotoxic T cells injury
to microvessel endothelial cells in various organs [2].
EPCs in Patients with Sclerodermatous Chronic GVHD 427As antibodies against host cells are detected in
cGVHD showing autoimmune disease-like manifesta-
tions [3], the pathophysiology of sclerodermatous
cGVHD (s-cGVHD) resembles to those observed in
progressive systemic sclerosis (PSS). PSS is character-
ized by vasculopathy [4], and a recent study revealed
that patients with PSS have low frequencies of circulat-
ing endothelial progenitor cells (EPCs), which impairs
vasculogenesis [5]. On the basis of the similarities with
PSS, we postulate that allo-SCT recipients with s-
cGVHD may also have low circulating EPC frequen-
cies. We retrospectively investigated the differences of
the circulating EPC numbers in the peripheral blood
(PB) and the ability of the PB mononuclear cells
(PBMNCs) to form endothelial cell colonies by using
the standard endothelial cell colony-forming unit
(CFU-EC) assay between normal volunteers and 27
allo-SCT patients, of which 5 developed s-cGVHD.
We showed that s-cGVHD patients had lower circu-
lating EPC frequencies and impaired endothelial col-
ony-forming potential, even though these patients
had elevated angiogenic cytokine levels in their serum.
MATERIALS AND METHODS
Patients
We recruited 27 allo-SCT patients and 14 healthy
volunteers. Allo-SCTwas performed at theDivision of
Hematology andOncology, Hospital of Kyoto Prefec-
tural University of Medicine, from November 1994
through to April 2006. All patients had maintained
complete remission at the time of the study. Acute
GVHD was diagnosed based on the standard criteria
[6-8], and cGVHDwas diagnosed based on the scoring
system of National Institute of Health Consensus De-
velopment Project on Criteria for Clinical Trials in
Chronic GVHD [9]. Acute GVHD occurred in 18 pa-
tients, whereas cGVHD occurred in 18 patients.
Healthy controls were age-matched volunteer donors.
PB samples were obtained from the 41 participants be-
tween June 2006 and April 2007. In accordance with
the Declaration of Helsinki recommendations, all pro-
cedures were approved by the institutional review
board at Kyoto Prefectural University of Medicine,
and written informed consent was obtained from every
participant. We collected PB from May through
November of 2006. PB was obtained once from each
patient at various time points after receiving the
allo-SCT, ranging from 69 days to 4432 days after
transplantation.
Quantification of Circulating CD341 Cells and
EPCs Frequencies
To quantify the CD341 cell frequencies in the PB,
we designed a flow cytometric gating strategy on the
basis of the International Society of Hematotherapyand Graft Engineering guidelines [10]. Thus, we
stained whole blood collected in ethylenediaminete-
traacetic acid (EDTA)-containing TruCOUNT tubes
(BD Bioscience, San Jose, CA) according to the manu-
facturer’s instructions. Briefly, 20 mL of fluorescein
isothiocyanate (FITC)-conjugated anti-CD45/phyco-
erythrin (PE)-conjugated anti-CD34 combination
(BD Bioscience) and 20 mL of 7-amino-actinomycin
D (7-AAD) were mixed with 50 mL of PB, and the mix-
ture was incubated at room temperature for 15 min-
utes. After red blood cell lysis, we used FACSCalibur
(BD Bioscience) to acquire 100,000 CD451 cells
events. There are counting beads in TruCOUNT
tubes and the frequency of CD341 cells/mL of whole
blood was calculated as follows: CD341 cells/mL 5
(number of CD341 cell events)  (number of beads
per test tube)/{(number of counted beads)  100}.
The mean frequency of CD341 cells in the PB was
obtained from 2 or 3 replicates.
The frequency of the EPCs in the PB was deter-
mined by isolating the PBMNCs from 20 mL heparin-
ized PB by Ficoll-Hypaque density centrifugation. The
CD341 cells were enriched from the PBMNCs by
using themagnetic cell sorting (MACS) separation sys-
tem (Miltenyi, Gladbach, Germany). The average
purity of the enriched CD341 cell populations was
86.5%. The sorted cells were then stained with
FITC-conjugated anti-CD34 mAb, PE-conjugated
antivascular endothelial growth factor receptor
(VEGFR)-2 mAb (R&D Systems, Minneapolis, MN),
and allophycocyanin-conjugated anti-CD133 mAb
(Miltenyi). Appropriate isotype control Abs served as
controls. Viable cells were identified by gating on their
forward and side scatters, and the expression by the
CD341 cells of VEGFR-2 and CD133 was assessed.
We defined EPCs as CD341/VEGFR-21/CD1331
cells [11,12] and calculated the circulating EPC fre-
quency as follows: EPCs /20 mL PB 5 (the absolute
number of CD341 cells/mL)  {(the number of events
of VEGFR-21/CD1331 cell events in the CD341 cell
gates)/(the number of events of CD341 cell events)} 
20,000.
Evaluation of CFU-ECs in the Peripheral Blood
We also determined the ability of the PBMNCs
from these patients to form endothelial cell colonies
by using the EndoCult Liquid Medium Kit (StemCell
Technologies, Vancouver, BC, Canada) according to
the manufacturer’s protocol. Briefly, PBMNCs were
resuspended in complete EndoCult medium and
seeded at 5  106 cells/well onto fibronectin-coated
tissue culture plates (BD Bioscience). After 48 hours,
the wells were washed with medium and the nonadher-
ent cells were collected and plated in their existing
medium at 106 cells/well into 24-well fibronectin-
coated tissue culture plates for 3 days. Colonies were
428 K. Shimura et al.defined as a central core of round cells surrounded by
elongated sprouting cells at the colony periphery. The
number of CFU-ECs was counted under an inverted
microscope in duplicate or triplicate. To confirm
that the colony cells are endothelial cells, fluorescent
staining was used to detect the binding of FITC-con-
jugated Ulex europaeus lectin (Sigma, St. Louis, MO)
and 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbo-
cyanine-labeled acetylated low-density lipoprotein
(acLDL) (Molecular Probes, Eugene, OR) [13]. We
also stained the colony cells with mAbs against endo-
thelial lineage surface markers. For this purpose, the
colony cells were harvested after treatment with
0.05% trypsin/EDTA (Gibco, Tokyo, Japan) and
were spun down onto slides by using Cytospin-3
(ThermoShandon, Cheshire, UK). The cells were
fixed with 2% paraformaldehyde, blocked with goat
immunoglobulin, and then incubated at 4C overnight
with mouse anti-CD31 mAb (Dako, Tokyo, Japan).
Thereafter, the cells were incubated with FITC-con-
jugated mouse specific mAb (Sigma) for 1 hour at
room temperature and then cells were incubated
with propidium iodide for 30 minutes at room temper-
ature. The stained cells were examined by FV1000
laser scanning confocal microscopy (Olympus, Tokyo,
Japan).
To confirm that the CFU-ECs obtained from the
recipients’ PBMNCs were of donor origin, the
CFU-ECs obtained from female patients who had re-
ceived stem cells from a male donor were subjected to
fluorescein in situ hybridization (FISH) analysis for
the Y-chromosome as previously described [14].
Briefly, the CFU-EC cells were centrifuged onto the
silane-coated glass slides described above, fixed in
Carnoy’s solution (methanol and acetic acid in a 3:1
ratio) for 10 minutes at ambient temperature, and
then air dried. After denaturation at 70C for 5 min-
utes in 70% formamide/2  saline sodium citrate
(SSC) (1 SSC consists of 0.15 M sodium chloride
and 0.015 M sodium citrate), the slides were dehy-
drated in an ethanol series at room temperature
and air dried. The probes mixture used to detect
the X and Y chromosomes (X chromosome, CEP X
(DXZ1); Y chromosome, CEP Y (DYZ1); Abbott
Vysis, Chiba, Japan) was denatured at 73C for 5 min-
utes, placed at 45C, and applied onto the slide. After
overnight hybridization in a humidified incubator at
37C, the slides were washed in 0.4  SSC/0.3%
NP40 solution at 73C for 30 minutes, then in 2 
SSC/0.1% NP40 solution at ambient temperature
for 1 day and air dried. The slides were then counter-
stained with 40, 6-diamidino-2-phenylindole (DAPI II,
Abbott Vysis) and mounted in Vectashield (Vector
Laboratories, Burlingame, CA). The FISH images
were analyzed by using a fluorescence microscope
BX40-RF (Olympus) and captured with a CCD cam-
era (SenSys0400-G1; Photometrics, Tucson, AZ).Evaluation of Angiogenic Cytokine Levels
in the Sera
We assessed the serum levels of VEGF and basic
fibroblast growth factor (b-FGF) by using specific
ELISA Kits (Quantikine, R&D Systems) according
to the manufacturer’s instructions.
Statistical Analysis
Comparison between any 2 groups of participants
was done by using the nonparametric Mann-Whitney
U test. In the case of cytokine levels under the lowest
detectable values by an ELISA kit, the median values
between 0 and the lowest detectable values were used
for the statistical analyses. The significance of differ-
ences between 2 groups analyzed by the Mann-Whit-
ney U test with the Bonferroni correction (3
comparisons in 3 groups) was considered to be signif-
icant at P\ .0167. The correlations between the num-
ber of circulating CD341 cells and EPCs, and the
examined days after transplantation were assessed us-
ing Spearman’s rank correlation test. P values\0.05
were considered to be statistically significant.
RESULTS
Patients Characeristics
The characteristics of the 27 allo-SCT patients are
shown in Table 1. The stem cell sources used for allo-
SCTwere bonemarrow (14 patients), PB (11 patients),
and umbilical cord blood (2 patients). PB was obtained
once from each patient at various time points after re-
ceiving the allo-SCT, ranging from 69 days to 4432
days after transplantation. Five patients developed s-
cGVHD around the 500th days after allo-SCT, 2 of
which had received PB and 3 of which received BM.
These patients were tested 593, 1250, 2163, 2257,
and 3708 days after transplantation, respectively. We
evaluated sclerodermatous lesions in s-cGVHD using
a modified Rodnan skin score, which is used for the
evaluations of skin lesions in PSS [15]. To assess the
extent of skin involvement, 17 body areas are palpated
and scored on the following scale: 0 5 normal, 1 5
thickened, 2 5 thickened, unable to move, and 3 5
thickened, unable to pinch (maximum score 5 51).
This scoring scale is used for the evaluations of s-
cGVHD [16]. The mean modified Rodnan skin score
of the s-cGVHD patients was 26.2.
Time Course of Circulating CD341 Cells and EPCs
Frequencies after allo-SCT
The PBs of the 27 patients and 14 healthy controls
were subjected to flow cytometric analysis to deter-
mine the circulating EPC frequencies. Circulating
EPCs were identified as CD341/CD1331/VEGFR-
21 cells. Representative flow cytometric data are
shown in Figure 1. The data of each patient was shown
Severity);
(Score)
Days after
SCT
Treatment at
Investigation
69 CsA
156 FK
I(2) 186 FK, PSL
(1), E(1), GI(2) 359 FK, PSL
GI(1) 395 FK, PSL
404 None
(1) 421 CsA, PSL
450 CsA, PSL
2) 697 CsA
(1), GI(1) 861 None
979 None
1019 FK, PSL
1211 PSL
), E(2), GI(2) 1354 PSL
1525 None
1535 None
1654 None
1704 PSL
2133 None
2256 None
2453 None
4432 None
2), E(1), J(2) 593 CsA, PSL
2), E(2), GI(2), Li(1), J(3) 1250 PSL
(1), E(2), GI(2), J(2) 2163 PSL
(2), E(2), GI(1), J(2) 2497 FK, PSL
(2), E(2),
u(1), J(3)
3708 PSL
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9Table 1. Patients’ Characteristics
Pt. Sex Age Disease
Conditioning
Regimen
Donor (Sex,
Relationship/Source)
Acute
GVHD
Chronic GVHD (
Organ or Site
Sclerodermatous chronic GVHD (2); n522
001 F 25 MDS CY 1 TBI F, Msib/PB None None
002 M 29 AML BU 1 CY F, MUD/BM Skin None
003 M 54 CML CY 1 TBI M, MUD/BM Skin, Gut Overlap (Severe) ; PS(2), M(2), G
004 M 58 AML Flu 1 l-PAM 1 TBI F, MMUD/UCB Skin Overlap (Severe) ; PS(2), S(2), M
005 F 38 MDS CY 1 TBI M, MMUD/BM None Classic (Moderate) ; PS(1), E(1),
006 F 35 AML CY 1 TBI M, MUD/BM Skin None
007 F 46 NHL CY 1 TBI F, Msib/PB None Classic (Severe) ; PS(1), M(2), E
008 M 60 CMML 2CdA 1 BU 1 TBI M, MUD/BM Skin Overlap (Severe) ; PS(1), S(3)
009 F 19 AML BU 1 CY F, Msib/PB Liver, Gut Overlap (Moderate) ; PS(1), GI(
010 M 34 ALL CY 1 TBI F, MUD/BM Skin Classic (Severe) ; PS(2), M(1), E
011 F 56 AML Flu 1 l-PAM M, Msib/BM None None
012 F 65 NHL Flu 1 l-PAM M, MMRD/PB Skin Overlap (Severe) ; PS(2), S(3)
013 M 36 AML CY 1 TBI F, MMUD/UCB Skin Classic (Mild) ; S(1)
014 M 48 MM Flu 1 l-PAM F, MMRD/PB Skin Overlap (Mild) ; PS(2), S(2), M(2
015 F 39 MDS CY 1 TBI F, Msib/PB Skin Overlap (Mild) ; S(1)
016 F 17 AA CY 1ATG M, Msib/BM None None
017 M 39 ALL CY 1 TBI M, MUD/BM Skin, Liver None
018 F 55 CML CY 1 TBI F, MMRD/PB Skin, Gut Classic (Moderate) ; M(2)
019 F 31 CML CY 1 TBI M, Msib/PB None Classic (Mild) ; PS(1), M(1)
020 M 23 AA CY 1ATG F, Msib/PB None None
021 F 33 CML CY 1 TBI F, MUD/BM Skin None
022 M 32 ALL BU 1 ETP 1 CY M, Msib/PB None None
Sclerodermatous chronic GVHD (1); n 5 5
023 M 52 AML CY 1 TBI F, MUD/BM None Classic (Severe) ; PS(1), S(3), M(
024 F 37 LCH CY 1 TBI F, Msib/PB Skin Classic (Severe) ; PS(3), S(3), M(
025 F 28 NHL Flu 1 CY M, Msib/PB Skin, Gut Overlap (Severe) ; PS(1), S(3), M
026 F 43 CML CY 1 TBI F, MUD/BM Skin, Liver Overlap (Severe) ; PS(3), S(3), M
027 F 27 ALL BU 1 CY 1 TBI M, MUD/BM Skin, Gut Overlap (Severe) ; PS(3), S(3), M
GI(2), Li(1), L
Pt. indicates patient; SCT, stem cell transplantation; GVHD, graft-versus-host disease; F, female; M, male; MDS, myelodysplastic syndrom
CML, chronic myelogenous leukemia; NHL, non-Hodgkin’s lymphoma; CMML, chronic myelomonocytic leukemia; ALL, acute lymphobl
LCH, Langerhans cell histiocytosis; CY, cyclophosphamide; TBL, total-body irradiation;, Flu, fludarabine; l-PAM, melphalan; 2CdA, 2
globulin; ETP, etoposide;Msib, matched sibling;MUD,matched unrelated donor;MMUD,mismatched unrelated donor;MMRD,misma
UCB, umbilical cord blood; PS, performance score; S, skin;M,mouth; E, eyes; GI, gastrointestinal tract; Li, liver; Lu, lungs; J, joints and fas
430 K. Shimura et al.Figure 1. Detection of EPCs in the PB. Representative flow cytometric data showing the detection of EPCs in the PB of a healthy vol-
unteer (A), a patient without s-cGVHD (B), and a patient with s-cGVHD (C). The upper right quadrant of the individual dot-plot images
contains the CD341/CD1331/VEGFR-21 EPCs. The frequency of EPCs in the gated CD341 cells and the absolute number of EPCs
detected in 20 mL of peripheral blood are shown in each panel. The graph (D) shows negative control data obtained by using isotype
control antibodies.in Table 2. The frequencies of circulating CD341 cells
and EPCs in the allo-SCT patients are shown in
Figure 2A and B, respectively. The correlations be-
tween the CD341 cell numbers and the days after
transplantation, and the EPC numbers and the days
in non-s-cGVHD patients are statistically significant
(Rs5 0.508; P5 .02, and Rs5 0.614; P5 .005, respec-
tively), whereas the correlations between the CD341
cell numbers and the days after transplantation, and
the EPC numbers and the days are not significantly
in all patients including the s-cGVHD patients (Rs 5
0.254; P5 .19, and Rs5 0.306; P5 .12, respectively).
These observations suggests that there could be
a time-dependent change in the circulating CD341
cell and EPC frequencies in the allo-SCT patients
without s-cGVHD and that the frequencies were
very low up until 500 days after transplantation, at
which point they started to recover and fall into the
normal donor range of frequencies. However, when
s-cGVHD was present, the frequencies of these cell
types remained low, which suggests that these patients
have impaired endothelial differentiation.Decreased Circulating CD341 Cells and EPCs
Frequencies Are Associated with s-cGVHD
To confirm that the s-cGVHD patients had lower
EPCs frequencies and had impaired endothelial differ-
entiation, we statistically compared the data of the 5 s-
cGHVD with those of the 14 non-s-cGVHD patients
who were tested.500 days after allo-SCT. This is be-
cause the s-cGVHD in our cases occurred about 500
days after allo-SCT, and it was around 500 days that
the CD341 cell and EPC frequencies started to
recover. The median CD341 cell frequencies of the
healthy volunteers, the 14 non-s-cGVHD, and the
s-cGVHD patients were 1.74/mL PB (interquartile
range [IQR] 1.34-2.01), 0.85 (0.73-1.62), and 0.41
(0.17-0.42), respectively (Figure 3A). The non-s-
cGVHD patients had significantly lower frequencies
than control (P 5 .018), whereas the s-cGVHD
patients had significantly lower frequencies when
compared to either the healthy volunteers (P 5
.0012) or non-s-cGVHD (P 5 .014) groups by the
Mann-WhitneyU test with the Bonferroni correction.
EPCs in Patients with Sclerodermatous Chronic GVHD 431Table 2. Absolute Numbers of CD34, EPCs, CFU-EC, and Serum Cytokine Levels
Patient CD34 (/mL) EPC (/20mL)
CFU-ECs
(/106 Nonadherent Cells) VEGF (pg/mL) b-FGF (pg/mL)
Sclerodermatous chronic GVHD (2); n 5 22
001 0.41 226 4 69 \10
002 0.43 130 1 \20 57
003 0.09 82 14 22 \10
004 3.49 551 16 34 \10
005 0.33 39 14 24 93
006 0.19 93 3 78 58
007 0.69 670 3 163 48
008 0.32 234 0 \20 55
009 0.61 620 27 \20 24
010 3.05 3573 23 148 23
011 0.74 1177 47 62 \10
012 0.72 1340 8 197 49
013 1.8 990 30 \20 12
014 0.73 192 36 154 39
015 2.33 3022 12 674 27
016 0.37 583 7 35 \10
017 0.93 817 6 22 29
018 1.83 2811 13 40 98
019 0.93 1581 10 30 12
020 0.77 500 32 27 24
021 0.75 964 8 97 21
022 1.09 2341 13 23 14
Sclerodermatous chronic GVHD (1); n 5 5
023 0.41 193 1 31 12
024 0.42 145 4 107 69
025 0.77 380 4 53 16
026 0.17 107 0 33 \10
027 0.11 63 5 168 81
EPC indicates endothelial progenitor cell; CFU-ECs, endothelial cell colony-forming unit; VEGF, vascular endothelial growth factor; b-FGF,
basic fibroblast growth factor.Thus, although hematopoiesis generally remains
slightly decreased after allo-SCT, patients with
s-cGVHD have very significantly impaired hemato-
poiesis as shown in the previous report [17]. A similar
analysis of the EPC frequencies revealed median
frequencies in the healthy volunteer, non-s-cGVHD,
and s-cGVHD groups of 1530.5 cells/20 mL (IQR
961.3-2158), 1083.5 (669.3-2151), and 145 (107-
193), respectively (Figure 3B). The difference between
the healthy volunteer and non-s-cGVHD groups was
not significant, as determined by the Mann-Whitney
U test with the Bonferroni correction. In contrast,
the s-cGVHD group had significantly lower EPC fre-
quencies than both the healthy volunteer and non-
s-cGVHD groups (P5 .0012 and .0023, respectively).
We investigated the frequencies of circulating EPCs of
non-s-cGVHD patients by divided into those with and
without c-GVHD. Those of the patients without
cGVHD and with cGVHD (without s-cGVHD)
were 1460.5, and 89.5/20mL of PB, respectively.
The frequencies of EPCs in s-cGVHD patients were
significantly lower than those in patients without c-
GVHD (P 5 .006) and with c-GVHD (P 5 .0084).
However, there was no significant difference betweenthose in patients without c-GVHD and with c-
GVHD (P 5 .197). We also evaluated the impacts of
immunosuppressants on the frequencies of circulating
EPCs in 14 patients who were tested .500 days after
allo-SCT. The medians of the EPC frequencies in
patients treated with and without the immunosuppres-
sants are 990, and 1177 cells/20mL of PB, respectively.
There were no significant differences (P 5 .549). Im-
munosuppression had no influences on the circulating
EPC frequencies. Taken together, the scleroderma-
tous changes in cGVHD have impacts on the circulat-
ing EPC frequencies after allo-SCT.
CFU-EC Assays Confirm Reduction of EPCs in
s-cGVHD Patients
We next assessed the ability of endothelial colony
in PBMNCsof each group.ThemedianCFU-ECnum-
bers per 106 nonadherent cells in the healthy volunteer,
non-s-cGVHD, and s-cGVHD groups were 26.4 (IQR
23.6-30.6), 12.8 (IQR 8.8-28.8), and 3.8 (IQR 1.0-4.3),
respectively (Figure 4A). The s-cGVHD patients had
significantly lower CFU-EC forming ability than the
other 2 groups (P 5 .0012 and .0012, respectively), as
determined by the Mann-Whitney U test with the
432 K. Shimura et al.Figure 2. Scattergrams showing the frequencies of CD341 cells (A) and EPCs (B) in the PB from normal donors, s-cGVHD patients, and non-
s-cGVHDpatients (with andwithout cGVHD) relative to when the PBs were obtained after allo-SCT.There was a clear time-dependent change
in the circulating CD341 cell (A) and EPC (B) frequencies in the allo-SCT patients, as the frequencies were very low up until 500 days after
transplantation, at which point they started to recover and fall into the normal donor range of frequencies. However, when s-cGVHDwas pres-
ent, the frequencies of these cell types remained low. Black triangles, white triangles, and red squares represent the absolute cell numbers in the
PB of non-s-cGVHD patients without cGVHD, non-s-cGVHDwith cGVHD, and s-cGVHD patients, respectively. Black circles represent the
absolute cell numbers in the PB of healthy volunteers.Bonferroni correction. We also assessed the phenotype
of the cells making up the colonies by fluorescent immu-
nostaining. The cells in the colonies from all 3 groups
showed lectin-binding activity and uptake of acLDL
(Figure 4B), and expressed the endothelial marker
CD31 (Figure 4C).
CFU-ECs Are Derived from Donor Cells
of allo-SCT
We next subjected the colonies from the patients
to FISH analysis to confirm that these cells were of do-
nor origin. There were too few colonies from the
s-cGVHDpatients to permit FISH analysis. However,
when the colonies from non-s-cGVHD femalepatients who had received male donor stem cells
were subjected to FISH, Y-FISH signal was detected
in over 95% of the 500 colony cells that were tested
(Figure 4D). Thus, it is likely that the circulating
CFU-ECs of all the allo-SCT patients were of donor
origin.
Allo-SCT Recipients Had Higher Levels of
Angiogenic Cytokines Than Healthy Volunteers
Last, we measured the serum levels of VEGF and
b-FGF (Figure 5). The non-s-cGVHD patients and
s-cGVHD had higher median VEGF levels (37.5
[IQR 24-135.3]) and 53 (33-107), respectively) than
the healthy volunteers (\20 [\20-24.8], P 5 .0015
EPCs in Patients with Sclerodermatous Chronic GVHD 433Figure 3.CD341 cell (A) and EPC (B) frequencies in the PB from normal donors, s-cGVHDpatients, and non-s-cGVHDpatients. The CD341
cell and EPC frequencies are expressed as cells per microliters and per 20mL of PB, respectively. The non-s-cGVHDpatients consist only of the
14 patients who gave PB.500 days after transplantation. In non-s-cGVHDpatients, white circles represent patients with cGVHD.The P values
were determined by using the Mann-Whitney U test with the Bonferroni correction.and P 5 .0012, respectively), as determined by the
Mann-WhitneyU test with the Bonferroni correction.
However, the VEGF levels of the 2 patient groups did
not differ significantly.With regard to the serum levels
of b-FGF, the non-s-cGVHD patients had signifi-
cantly higher median levels (23.5 IQR [12.5-28.5])
than the healthy volunteers (\10 [\10-11.75], P 5
.0012), whereas the s-cGVHD patients tended to
have higher levels (16 [12-69]) than the normal donors
(P5 .04). A significant difference in b-FGF levels was
not observed between the 2 patient groups.
DISCUSSION
We showed here that within the first 500 days after
allo-SCT, the circulating CD341 cell and EPC fre-
quencies in patient PBs were extremely low but that
these frequencies then recovered to normal levels.
However, if the patients developed s-cGVHD, which
our 5 patients did around the 500th day after trans-
plantation, their CD341 cell and EPC frequencies
remained low. Compared to healthy volunteers or
non-s-cGVHD patients who were tested .500 days
after allo-SCT, the s-cGVHD patients also formed
endothelial cell colonies significantly less. The previ-
ous report demonstrated that the number of circulat-
ing EPCs is decreased in patients with PSS [5].
According to this report that the estimation of the cir-
culating EPC numbers was performed by the similar
flow cytometric procedures, the number of circulating
CD341/CD1331/VEGFR-21 EPCs from healthy
volunteers (the median number 5 1074/20 mL of
PB) is as high as that in our study (the median number
5 1530.5/20 mL of PB). Because the frequencies ofcirculating EPCs in patients with PSS (the median
number 5 274/20 mL of PB) is as low as that in pa-
tients with s-cGVHD (the median number 5 145/20
mL of PB), we concluded that the circulating EPCs
frequencies are decreased in the patients with s-
cGVHD similar to those in the patients with PSS.
Total-body irradiation (TBI) and/or chemother-
apy are used as a conditioning regimen in allo-
SCT. To evaluate the role of TBI as a potential cause
for decreased CD341 cells and EPCs, we compared
these frequencies in patients who received TBI-con-
taining regimen and in those who received non-TBI
regimen. There were no significant differences be-
tween them (data not shown). Regardless of TBI,
the conditioning regimen not only injures endothelial
cells [18] but also damages the bone marrow (BM)
stromal function [17], which decreases the number
of progenitors in the BM. This probably explains
why the allo-SCT recipients had lower circulating
CD341 cell frequencies shortly after transplantation
compared to healthy volunteers. Because EPCs are
derived from CD341 hematopoietic cells [19], the
conditioning regimen is probably also responsible
for low EPC frequencies observed after allo-SCT.
Supporting this is our FISH analysis, which showed
that the circulating EPCs in the recipients are of do-
nor origin. Thus, the conditioning regimen damages
hematopoiesis and impairs the production of EPCs
after allo-SCT. Subsequently, hematopoiesis from
the donor stem cells then begins occurring. An eleva-
tion in angiogenic cytokines production then stimu-
lates the EPCs to mobilize into the PB. These
events lead to a recovery in circulating EPC numbers
and endothelial cell colony formation potential.
434 K. Shimura et al.Figure 4. Endothelial cell differentiation potential of nonadherent PBMNCs from the normal donors, s-cGVHD patients, and non-s-cGVHD
patients. The number of CFU-ECs per 106 nonadherent PBMNCs from each participant is shown in (A). The non-s-cGVHD patients consist
only of the 14 patients who gave PB.500 days after transplantation. In non-s-cGVHD patients, white circles represent patients with cGVHD.
The P values were determined by using the Mann-Whitney U test with the Bonferroni correction. The colony cells had lectin-binding activity
and took up of acLDL (B), and expressed CD31 (C). FISH analysis revealed the Y-chromosome signal in the colony cells from female patients
who had received male donor stem cells (D). The white bars represent 100 mm (B), 5 mm (C), and 10 mm (D).
EPCs in Patients with Sclerodermatous Chronic GVHD 435Figure 5. Serum VEGF (A) and b-FGF (B) levels in the normal donors, the non-s-cGVHD patients consist only of the 14 patients who gave
PB .500 days after transplantation. In non-s-cGVHD patients, white circles represent patients with cGVHD. The P values were determined
by using the Mann-Whitney U test with the Bonferroni correction.It has been suggested previously that patients with
cGVHD have a profound and sustained impairment of
hematopoiesis [17]. This may suppress the production
of EPCs in the bone marrow, and reduce CD341 cell
and EPC frequencies in the PB of the severe form of
cGVHD such as s-cGVHD. In this study, s-cGVHD
patients show findings consistent with those seen in
PSS with impaired vasculogenesis [5]. Two mecha-
nisms contribute to postnatal neovascularization. In
the first, new blood vessels are produced from preexist-
ing vessels by the sprouting of differentiated ECs (an-
giogenesis). In the second mechanism, EPCs are
mobilized from the bone marrow and construct de
novo blood vessels (vasculogenesis). Circulating EPCs
are important to the process of vascular repair. The
EPC numbers reflect vascular disease and impairment
of vasculogenesis [20-22] and vasculogenesis contrib-
utes to vascular healing in response to vascular injuries
or ischemia [23,24]. It is speculated that the decrease
of EPCs frequencies may limit blood perfusion and
may contribute to the development of sclerodermatous
lesions in s-cGVHD patients as seen in patients with
PSS.
In the present study, there were no differences of
serum levels of angiogenic factors between the patients
with and without s-cGVHD. The reasons why EPCs
frequencies did not increase in the s-cGVHD patientsdesptie and increase of angiogenic factors could be that
the EPCs themselves are damaged in s-cGVHD pa-
tients. One possibility is that EPCs may be exhausted
by repairing the endothelial injuries of s-cGVHD.
Del Papa et al. [25] described that the circulating
EPCs are decreased despite the elevated serum
VEGF levels in advanced PSS patients. They showed
the decrease of CD1331 EPCs in the BM of advanced
PSS patients and speculated that the decrease of the
circulating EPCs is caused by the exhaustion of
EPCs in the BM. We did not estimate the number of
EPCs in the BM. However, the impairment of the he-
matopoiesis because of cGVHD could induce the de-
crease of EPCs in the BM. In addition to this, the
mobilization of EPCs into the PB for the repairing en-
dothelial injuries might have decreased further. The
second possibility is that the EPCs in s-cGVHD pa-
tients may be functionally altered such that they be-
come intrinsically hyporesponsive to angiogenic
stimuli. A similar EPC dysfunction is observed in pa-
tients with diabetes mellitus type II [26]. As a result
of this functional alteration of EPCs, endothelial col-
ony formation and the mobilization of EPCs into the
PB is impaired even though high levels of angiogenic
cytokines such as VEGF and b-FGF are being pro-
duced. A third possibility to explain the low EPC fre-
quencies in s-cGVHD patients is that EPC apoptosis
436 K. Shimura et al.may be increased in these patients. Supporting this is
the fact that patients with coronary artery disease
show continuous endothelial injury that may deplete
the circulating EPC frequencies [20]. Moreover,
EPCs have been shown to be sensitive to apoptotic in-
duction [27]. Thus, it is possible that the transplanted
stem cells or EPCs in s-cGVHD patients may be in-
duced to apoptosis because of the chronic endothelial
injury caused by GVHD [2]. Taken together, we spec-
ulated that the EPC frequencies are decreased in the s-
cGHHD patients despite the lack of differences in the
levels of the measeured angiogenic factors between s-
cGVHD and non-s-cGVHD patients. Although the
low EPC frequencies in s-cGVHDpatients may be be-
cause of an imbalance between the angiogenic and an-
giostatic cytokines, we did not measure the serum
levels of angiostatic cytokines like endostatin. It re-
mains possible that s-cGVHD patients may be pro-
ducing high levels of angiostatic factors that could
suppress the differentiation or maturation of EPCs.
Recently it was reported that true EPCs are
not CD341/CD1331/VEGFR-21 cells, but CD341/
CD452 cells [28]. However, the hematopoietic origin
CD341/CD1331/VEGFR-21 EPCs can differentiate
into endothelial cells. These cells may be mainly re-
sponsible for maintaining the level of circulating
EPCs and angiogenic capacity of wound or ischemic
tissue [23]. Therefore, our results indicate that the
poor recovery of circulating EPCs after allo-SCT is
predictive for s-cGVHD characterized by poor vascu-
larity in the skin lesions [2].
In conclusion, we demonstrated that the circulat-
ing EPCs frequencies and the ability of endothelial
colony formation of PBMNCs are decreased in s-
cGVHD patients after allo-SCT. It remains unclear
how to treat cGVHD, in particular s-cGVHD, al-
though several promising therapies are available
[29,30]. It is possible that circulating EPC frequencies
and endothelial cell colony formation ability may be
good markers that indicate responsiveness to therapy.
Moreover, our observations suggest that s-cGVHD
patients develop sclerodermatous lesions because
they suffer blood vessel loss because of chronic endo-
thelial injury and low EPC frequencies; this, in turn,
may impair blood perfusion and fibrosis of the skin, re-
sulting in the development of sclerodermatous lesions
in the patients with cGVHD. Given that relatively few
s-cGVHD patients were examined in the present
study, additional, more extensive, studies are needed
to confirm these theories.
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